Orchestra BioMed (OBIO) to Release Earnings on Wednesday

Orchestra BioMed (NASDAQ:OBIO) is anticipated to issue its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.38) per share and revenue of $0.9310 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 7:00 AM ET.

Orchestra BioMed (NASDAQ:OBIO) last announced its quarterly earnings data on Thursday, March 12th. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.64. Orchestra BioMed had a negative net margin of 157.40% and a negative return on equity of 184.17%. The firm had revenue of $30.92 million during the quarter, compared to the consensus estimate of $0.93 million. On average, analysts expect Orchestra BioMed to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Orchestra BioMed Stock Performance

Shares of OBIO stock opened at $4.66 on Wednesday. The company has a market cap of $272.70 million, a price-to-earnings ratio of -4.12 and a beta of 0.56. The stock has a 50 day simple moving average of $4.19 and a 200-day simple moving average of $3.95. Orchestra BioMed has a 12-month low of $2.20 and a 12-month high of $5.42. The company has a current ratio of 6.45, a quick ratio of 6.43 and a debt-to-equity ratio of 0.27.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on OBIO shares. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of Orchestra BioMed in a report on Thursday, March 12th. TD Cowen assumed coverage on shares of Orchestra BioMed in a research report on Wednesday, December 10th. They set a “buy” rating on the stock. Wall Street Zen raised shares of Orchestra BioMed from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, Barclays increased their price target on shares of Orchestra BioMed from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $14.25.

Insider Transactions at Orchestra BioMed

In other news, insider David P. Hochman acquired 10,000 shares of Orchestra BioMed stock in a transaction that occurred on Friday, March 13th. The stock was purchased at an average cost of $4.29 per share, with a total value of $42,900.00. Following the completion of the acquisition, the insider owned 1,086,467 shares in the company, valued at $4,660,943.43. This trade represents a 0.93% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Creative Planning purchased a new position in Orchestra BioMed during the 2nd quarter valued at about $40,000. XTX Topco Ltd acquired a new position in shares of Orchestra BioMed during the 2nd quarter worth approximately $45,000. Jane Street Group LLC acquired a new position in shares of Orchestra BioMed during the 2nd quarter worth approximately $50,000. Virtu Financial LLC purchased a new stake in Orchestra BioMed in the 4th quarter valued at approximately $57,000. Finally, Bank of America Corp DE lifted its stake in Orchestra BioMed by 35.7% in the 2nd quarter. Bank of America Corp DE now owns 21,577 shares of the company’s stock valued at $58,000 after buying an additional 5,678 shares in the last quarter. Hedge funds and other institutional investors own 53.20% of the company’s stock.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.